

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1181344
<b>Application Number:</b>	10715055
<b>Confirmation Number:</b>	3314
<b>Title of Invention:</b>	Antibiotic compositions for treatment of the eye, ear and nose
<b>First Named Inventor:</b>	Gerald Cagle
<b>Customer Number:</b>	26356
<b>Filer:</b>	PAUL M RIVARD/Laura Sunderland
<b>Filer Authorized By:</b>	PAUL M RIVARD
<b>Attorney Docket Number:</b>	1732 US F2
<b>Receipt Date:</b>	31-AUG-2006
<b>Filing Date:</b>	17-NOV-2003
<b>Time Stamp:</b>	17:01:48
<b>Application Type:</b>	Utility
<b>International Application Number:</b>	

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 920
RAM confirmation Number	419
Deposit Account	190733
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Request for Continued Examination (RCE)	710900001rce.pdf	34431	no	1
<b>Warnings:</b>					
<b>Information:</b>					
2	Amendment Submitted/Entered with Filing of CPA/RCE	710900001requestforreconsideration.pdf	32342	no	3
<b>Warnings:</b>					
<b>Information:</b>					
3	Terminal Disclaimer Filed	701900001_terminaldisclaimer.pdf	108529	no	3
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	Bayer_and_Alcon_Complaint.pdf	425687	no	10
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	Communicationdated62806fromEPO.pdf	6014563	no	132
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	DeclarationofDavidWStromann.pdf	2473822	no	55
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	letterfromEPassociate_datedJuly142006inEPOpposition.pdf	2200214	no	28
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	letterfromEPassociate_datedJuly282006_inEPOpposition.pdf	71174	no	1
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	lettertoEPO_datedJuly122006_inrelatedEPOpposition.pdf	3566466	no	41
<b>Warnings:</b>					

<b>Information:</b>					
10	NPL Documents	noticeofopposition.pdf	1593758	no	51
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Summons_to_attendoraproceeding.pdf	189052	no	4
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Teva_Para_4_CertLtr.pdf	1042773	no	19
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	TexasAnswerstoComplaint.pdf	236127	no	8
<b>Warnings:</b>					
<b>Information:</b>					
14	Information Disclosure Statement (IDS) Filed	701900001ids.pdf	1386513	no	6
<b>Warnings:</b>					
<b>Information:</b>					
15	Fee Worksheet (PTO-875)	fee-info.pdf	8305	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			19383756		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					